Market Place
Sourcing Support
Hutchmed to Receive Milestone Payment for FRUZAQLA® Reimbursement
12 Dec 2024 //
GLOBENEWSWIRE
Hutchmed Announces Launch by Takeda of FRUZAQLA in Japan
21 Nov 2024 //
GLOBENEWSWIRE
HUTCHMED to Receive Milestone Payment for FRUZAQLA® Sales
31 Oct 2024 //
GLOBENEWSWIRE
HUTCHMED Announces Japan Approval For FRUZAQLA By Takeda
23 Sep 2024 //
GLOBENEWSWIRE
HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf
08 Sep 2024 //
GLOBENEWSWIRE
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
29 Aug 2024 //
GLOBENEWSWIRE
Takeda Receives EU Approval for FRUZAQLA
22 Jun 2024 //
PRESS RELEASE
Takeda Pharmaceutical`s Fruzaqla (fruquintinib) Receives Approval in Europe
20 Jun 2024 //
EMA
Takeda: Positive CHMP Opinion for Fruquintinib in mCRC
26 Apr 2024 //
BUSINESSWIRE
HUTCHMED & Innovent NDA Acceptance in China for Fruquintinib with Sintilimab
01 Apr 2024 //
GLOBENEWSWIRE
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib
06 Feb 2024 //
GLOBENEWSWIRE
HUTCHMED Receives ELUNATE (fruquintinib) Marketing Approval in Hong Kong
29 Jan 2024 //
GLOBENEWSWIRE
HUTCHMED has Completed Enrollment of Ph II/III of Fruquintinib with Sintilimab
12 Dec 2023 //
GLOBENEWSWIRE
HUTCHMED Announces Continued Inclusion of ELUNATE and SULANDA
12 Dec 2023 //
GLOBENEWSWIRE
FRUZAQLA™ (fruquintinib) Now Available from Onco360
21 Nov 2023 //
BUSINESSWIRE
Fruquintinib Becomes First Antineoplastic Drug to Be Prescribed in US
17 Nov 2023 //
YICAIGLOBAL
Takeda`s colorectal cancer drug Fruzaqla cleared by FDA
09 Nov 2023 //
PRESS RELEASE
Hutchmed Receives BTD for Fruquintinib Combination with Sintilimab
19 Jul 2023 //
GLOBENEWSWIRE
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
15 Jun 2023 //
PRESS RELEASE
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib
25 May 2023 //
GLOBENEWSWIRE
HUTCHMED Announces NDA Acceptance in China for Fruquintinib
17 Apr 2023 //
GLOBENEWSWIRE
Takeda, Hutchmed hook up on cancer drug for $1.13B
24 Jan 2023 //
FIERCE PHARMA
HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib
19 Dec 2022 //
GLOBENEWSWIRE
Hutchmed`s fruquintinib posts China trial win in second-line gastric cancer
15 Nov 2022 //
FIERCEPHARMA
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib with Sintilimab
27 Oct 2022 //
GLOBENEWSWIRE
HUTCHMED`s Fruquintinib Global PIII FRESCO-2 Study Has Met Its Primary Endpoint
07 Aug 2022 //
GLOBENEWSWIRE
ELUNATE receives commercial approval in Macau
01 Mar 2022 //
PHARMAFILE
HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at 2022 ASCO GI
18 Jan 2022 //
GLOBENEWSWIRE
Hutchmed completes enrollment of FRESCO-2 in phase III trial of fruquintinib
08 Dec 2021 //
PHARMABIZ
Hutchmed announces agreement with NHSA for adding oncology drugs Elunat
06 Dec 2021 //
PHARMABIZ
HUTCHMED Completes Enrollment of FRESCO-2, Ph III Trial of Fruquintinib
05 Dec 2021 //
GLOBENEWSWIRE
Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib
04 Sep 2020 //
CHI-MED
Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO
24 Aug 2020 //
PRESS RELEASE
Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China
29 Jul 2020 //
PRESS RELEASE
Innovent and Chi-Med Expand Global Collaboration
11 Oct 2019 //
PR NEWSWIRE
Chi-Med cuts surufatinib PhIII short
17 Jun 2019 //
ENDPTS
Oncology dominates a ‘Cambrian explosion’ in China’s drug pipeline
18 Mar 2019 //
ENDPTS
Chi-Med and Lilly’s cancer drug Elunate a milestone for China
26 Nov 2018 //
PM LIVE
After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer
17 Nov 2018 //
FIERCE PHARMA
Eli Lilly partner Chi-Med shares tank as Newly approved cancer drug flunks PhIII
16 Nov 2018 //
ENDPTS
Can A Cancer Drug Originated In China Be A Success In The U.S.?
13 Sep 2018 //
FORBES
Boost for `made in China` medicine as Chi-Med wins key approval
05 Sep 2018 //
REUTERS
Effect of Fruquintinib vs Placebo on Overall Survival in Patients
29 Jun 2018 //
JAMANETWORK
